Cisplatin or LA-12 enhance killing effects of TRAIL in prostate
cancer cells through Bid-dependent stimulation of mitochondrial
apoptotic pathway but not caspase-10

J 2017

Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10

BLANAROVA, O., Barbora ŠAFAŘÍKOVÁ, Jarmila HERŮDKOVÁ, Martin KRKOŠKA, S. TOMANKOVA et. al.

Základní údaje

Originální název

Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10

Autoři

BLANAROVA, O. (203 Česká republika), Barbora ŠAFAŘÍKOVÁ (203 Česká republika, domácí), Jarmila HERŮDKOVÁ (703 Slovensko, domácí), Martin KRKOŠKA (203 Česká republika, domácí), S. TOMANKOVA (203 Česká republika), Z. KAHOUNOVA (203 Česká republika), L. ANDERA (203 Česká republika), J. BOUCHAL (203 Česká republika), G. KHARAISHVILI (203 Česká republika), M. KRAL (203 Česká republika), P. SOVA (203 Česká republika), Alois KOZUBÍK (203 Česká republika, domácí) a A. HYRŠLOVÁ VACULOVÁ (203 Česká republika, garant)

Vydání

Plos one, San Francisco, Public Library of Science, 2017, 1932-6203

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10601 Cell biology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.766

Kód RIV

RIV/00216224:14310/17:00100456

Organizační jednotka

Přírodovědecká fakulta

DOI

http://dx.doi.org/10.1371/journal.pone.0188584

UT WoS

000416402000040

Klíčová slova anglicky

X-LINKED INHIBITOR; PLATINUM(IV) COMPLEX LA-12; CYTOCHROME-C; ANTITUMOR EFFICACY; IN-VITRO; DEATH; LIGAND; THERAPY; PROTEIN; MANNER

Štítky

NZ, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 30. 3. 2018 08:33, Ing. Nicole Zrilić

Anotace

V originále

Searching for new strategies for effective elimination of human prostate cancer cells, we investigated the cooperative cytotoxic action of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and two platinum-based complexes, cisplatin or LA-12, and related molecular mechanisms. We demonstrated a notable ability of cisplatin or LA-12 to enhance the sensitivity of several human prostate cancer cell lines to TRAIL-induced cell death via an engagement of mitochondrial apoptotic pathway. This was accompanied by augmented Bid cleavage, Bak activation, loss of mitochondrial membrane potential, activation of caspase-8, -10, -9, and -3, and XIAP cleavage. RNAi-mediated silencing of Bid or Bak in Bax-deficient DU 145 cells suppressed the drug combination-induced cytotoxicity, further underscoring the involvement of mitochondrial signaling. The caspase-10 was dispensable for enhancement of cisplatin/LA-12 and TRAIL combination-induced cell death and stimulation of Bid cleavage. Importantly, we newly demonstrated LA-12-mediated enhancement of TRAIL-induced cell death in cancer cells derived from human patient prostate tumor specimens. Our results provide convincing evidence that employing TRAIL combined with cisplatin/LA-12 could contribute to more effective killing of prostate cancer cells compared to the individual action of the drugs, and offer new mechanistic insights into their cooperative anticancer action.

Citovat

BLANAROVA, O., Barbora ŠAFAŘÍKOVÁ, Jarmila HERŮDKOVÁ, Martin KRKOŠKA, S. TOMANKOVA, Z. KAHOUNOVA, L. ANDERA, J. BOUCHAL, G. KHARAISHVILI, M. KRAL, P. SOVA, Alois KOZUBÍK a A. HYRŠLOVÁ VACULOVÁ. Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10. Plos one. San Francisco: Public Library of Science, 2017, roč. 12, č. 11, s. 1-23. ISSN 1932-6203. Dostupné z: https://dx.doi.org/10.1371/journal.pone.0188584.

@article{1412026,
   author = {Blanarova, O. and Šafaříková, Barbora and Herůdková, Jarmila and Krkoška, Martin and Tomankova, S. and Kahounova, Z. and Andera, L. and Bouchal, J. and Kharaishvili, G. and Kral, M. and Sova, P. and Kozubík, Alois and Hyršlová Vaculová, A.},
   article_location = {San Francisco},
   article_number = {11},
   doi = {http://dx.doi.org/10.1371/journal.pone.0188584},
   keywords = {X-LINKED INHIBITOR; PLATINUM(IV) COMPLEX LA-12; CYTOCHROME-C; ANTITUMOR EFFICACY; IN-VITRO; DEATH; LIGAND; THERAPY; PROTEIN; MANNER},
   language = {eng},
   issn = {1932-6203},
   journal = {Plos one},
   title = {Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10},
   volume = {12},
   year = {2017}
}

TY  - JOUR
ID  - 1412026
AU  - Blanarova, O. - Šafaříková, Barbora - Herůdková, Jarmila - Krkoška, Martin - Tomankova, S. - Kahounova, Z. - Andera, L. - Bouchal, J. - Kharaishvili, G. - Kral, M. - Sova, P. - Kozubík, Alois - Hyršlová Vaculová, A.
PY  - 2017
TI  - Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10
JF  - Plos one
VL  - 12
IS  - 11
SP  - 1-23
EP  - 1-23
PB  - Public Library of Science
SN  - 19326203
KW  - X-LINKED INHIBITOR
KW  - PLATINUM(IV) COMPLEX LA-12
KW  - CYTOCHROME-C
KW  - ANTITUMOR EFFICACY
KW  - IN-VITRO
KW  - DEATH
KW  - LIGAND
KW  - THERAPY
KW  - PROTEIN
KW  - MANNER
N2  - Searching for new strategies for effective elimination of human prostate cancer cells, we investigated the cooperative cytotoxic action of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and two platinum-based complexes, cisplatin or LA-12, and related molecular mechanisms. We demonstrated a notable ability of cisplatin or LA-12 to enhance the sensitivity of several human prostate cancer cell lines to TRAIL-induced cell death via an engagement of mitochondrial apoptotic pathway. This was accompanied by augmented Bid cleavage, Bak activation, loss of mitochondrial membrane potential, activation of caspase-8, -10, -9, and -3, and XIAP cleavage. RNAi-mediated silencing of Bid or Bak in Bax-deficient DU 145 cells suppressed the drug combination-induced cytotoxicity, further underscoring the involvement of mitochondrial signaling. The caspase-10 was dispensable for enhancement of cisplatin/LA-12 and TRAIL combination-induced cell death and stimulation of Bid cleavage. Importantly, we newly demonstrated LA-12-mediated enhancement of TRAIL-induced cell death in cancer cells derived from human patient prostate tumor specimens. Our results provide convincing evidence that employing TRAIL combined with cisplatin/LA-12 could contribute to more effective killing of prostate cancer cells compared to the individual action of the drugs, and offer new mechanistic insights into their cooperative anticancer action.
ER  -

BLANAROVA, O., Barbora ŠAFAŘÍKOVÁ, Jarmila HERŮDKOVÁ, Martin KRKOŠKA, S. TOMANKOVA, Z. KAHOUNOVA, L. ANDERA, J. BOUCHAL, G. KHARAISHVILI, M. KRAL, P. SOVA, Alois KOZUBÍK a A. HYRŠLOVÁ VACULOVÁ. Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10. \textit{Plos one}. San Francisco: Public Library of Science, 2017, roč.~12, č.~11, s.~1-23. ISSN~1932-6203. Dostupné z: https://dx.doi.org/10.1371/journal.pone.0188584.

Podrobný výpis o publikaci